Antigen-Presenting Fibroblasts Found in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC), which is for the most part resistant to chemotherapy and lacks effective treatments, is the fourth leading cause of cancer-related death worldwide. Researchers have now identified a potential therapeutic target in this deadly disease: antigen-presenting fibroblasts. "We can't diagnose patients [with PDAC] early enough because we don't have tools, and they don't respond to drugs. One barrier to the drugs is the fibroblasts in the stroma...
Continue reading

Olaparib Maintenance for Metastatic Pancreatic Cancer

The phase 3 POLO trial (NCT02184195) reports that maintenance olaparib increases progression-free survival in metastatic pancreatic cancer with germline BRCA mutations. "Metastatic pancreatic cancer is particularly refractory to treatment," Talia Golan, MD, Head of the Sheba Pancreatic Cancer Center at the Oncology Institute of Tel Aviv University's Sheba Medical Center, and colleagues remark in their publication in The New England Journal of Medicine . "Current standard-of-care first-line ...
Continue reading

PARP Inhibitor Effective in Advanced Pancreatic Cancer

Poly (ADP-ribose) polymerase (PARP) inhibitors, such as rucaparib (Rubraca®, Clovis Oncology), have been shown to be effective for cancers containing BRCA mutations. They have also been successful as maintenance therapy for platinum-sensitive ovarian cancer treated with PARP inhibitors. Therefore, researchers conducted a phase 2 clinical trial to determine if patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic BRCA or PALB2 mutation whose cancer had n...
Continue reading

Targeting KRAS-Driven Pancreatic Cancer

​ The most common form of pancreatic cancer, pancreatic ductal adenocarcinoma is highly difficult to treat, with a five-year survival rate of only 8%. There is one therapeutic target that has led to encouraging preclinical results: inhibition of oncogenic KRAS, a mutation that is present in over 90% of pancreatic ductal adenocarcinomas. However, in mouse models of this disease, genetic extinction of oncogenic Kras has resulted in recurrence that no longer relies on the Kras oncogene. For this re...
Continue reading

Overprescribing Preventive Drugs to Elderly Patients With Advanced Cancer

Researchers discovered that elderly patients with advanced cancer who continue to take some preventive drugs might not achieve clinical benefit during their remaining lifespan, thereby rendering the drugs unnecessary money and time wasters. In this study, published in Cancer, the investigators found that in 151,201 adults older than 65 with advanced cancer who passed away, patients were prescribed an average of 6.9 to 10.1 drugs over the last year of their life. Preventive drugs, such as antihyp...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.